C. Sebban

发表

An information retrieval system for computerized patient records in the context of a daily hospital practice: the example of the Léon Bérard Cancer Center (France)

P. Biron, M. Metzger, C. Pezet, 2014, Applied Clinical Informatics.

Tumor necrosis factor alpha release is a major biological event associated with rituximab treatment.

G. Salles, B. Coiffier, O. Casasnovas, 2001, The hematology journal : the official journal of the European Haematology Association.

Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study.

J. Rossi, G. Salles, R. Bouabdallah, 2008, Blood.

High total metabolic tumor volume at baseline predicts survival independent of response to therapy

L. Vercellino, P. Gaulard, G. Salles, 2020 .

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial

Andrew Lister, Anne Sonet, Hervé Tilly, 2011, The Lancet.

Updated 6 Year Follow-Up Of The PRIMA Study Confirms The Benefit Of 2-Year Rituximab Maintenance In Follicular Lymphoma Patients Responding To Frontline Immunochemotherapy

A. Hagenbeek, G. Salles, A. López-Guillermo, 2013 .

Risk model for severe anemia requiring red blood cell transfusion after cytotoxic conventional chemotherapy regimens. The Elypse 1 Study Group.

J. Blay, A. Ravaud, A. Le Cesne, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Identification of patients at risk for early death after conventional chemotherapy in solid tumours and lymphomas

J. Blay, P. Biron, C. Sebban, 2001, British Journal of Cancer.

Baseline and early lymphopenia predict for the risk of febrile neutropenia after chemotherapy

J. Blay, A. Le Cesne, P. Biron, 2003, British Journal of Cancer.

Evaluation of core needle biopsy as a substitute to open biopsy in the diagnosis of soft-tissue masses.

P. Biron, C. Sebban, I. Ray-Coquard, 2003, European journal of cancer.

Elderly patients with aggressive non-Hodgkin's lymphoma: disease presentation, response to treatment, and survival--a Groupe d'Etude des Lymphomes de l'Adulte study on 453 patients older than 69 years.

J. Blay, B. Coiffier, H. Tilly, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Transplantation with selected autologous peripheral blood CD34+Thy1+ hematopoietic stem cells (HSCs) in multiple myeloma: impact of HSC dose on engraftment, safety, and immune reconstitution.

G. Salles, B. Coiffier, H. Godinot, 2000, Experimental hematology.

Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial.

J. Raemaekers, R. Bouabdallah, A. Stamatoullas, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of gemcitabine-dexamethasone with or without cisplatin in relapsed or refractory mantle cell lymphoma.

B. Coiffier, R. Bouabdallah, C. Sebban, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trial.

D. Esseltine, B. Pégourié, B. Grosbois, 2011, Blood.

Comparison of Three Radiation Dose Levels after EBVP Regimen in Favorable Supradiaphragmatic Clinical Stages (CS) I-II Hodgkin’s Lymphoma (HL): Preliminary Results of the EORTC-GELA H9-F Trial.

C. Sebban, M. Henry-Amar, E. Noordijk, 2005 .

CD4 lymphopenia to identify end-of-life metastatic cancer patients.

J. Blay, P. Biron, C. Sebban, 2013, European journal of cancer.

How to define intermediate stage in Hodgkin's lymphoma?

C. Gisselbrecht, C. Sebban, N. Mounier, 2005, European journal of haematology. Supplementum.

Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients.

G. Salles, F. Berger, B. Coiffier, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor?

O. Decaux, C. Sebban, P. Moreau, 2011, Blood.

Smoking and non-Hodgkin's lymphoma: a case–control study in the Rhône-Alpes region of France

B. Coiffier, A. Sasco, C. Sebban, 2003, Cancer Causes & Control.

Premature ovarian failure and fertility in long-term survivors of Hodgkin's lymphoma: a European Organisation for Research and Treatment of Cancer Lymphoma Group and Groupe d'Etude des Lymphomes de l'Adulte Cohort Study.

J. Raemaekers, A. Allgeier, E. Noordijk, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Parma Group.

J. Blay, A. Hagenbeek, P. Biron, 1998, Blood.

CD4 lymphopenia as a risk factor for febrile neutropenia and early death after cytotoxic chemotherapy in adult patients with cancer

J. Blay, P. Biron, C. Sebban, 2004, Cancer.

A Prospective Study Of The LMB Regimen For Diffuse Large Cell Non Hodgkin's Lymphoma In Adults

J. Blay, P. Biron, C. Sebban, 2000, Leukemia & lymphoma.

Effect of granulocyte colony-stimulating factor administration in elderly patients with aggressive non-Hodgkin's lymphoma treated with a pirarubicin-combination chemotherapy regimen. Groupe d'Etudes des Lymphomes de l'Adulte.

B. Coiffier, H. Tilly, C. Gisselbrecht, 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II trial of fludarabine monophosphate as first-line treatment in patients with advanced follicular lymphoma: a multicenter study by the Groupe d'Etude des Lymphomes de l'Adulte.

H. Tilly, N. Brousse, C. Sebban, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Single or tandem autologous stem-cell transplantation for first-relapsed or refractory Hodgkin lymphoma: 10-year follow-up of the prospective H96 trial by the LYSA/SFGM-TC study group

G. Salles, R. Bouabdallah, C. Sebban, 2016, Haematologica.

lymphoma patients: results of the GELA-GOELAMS FL2000 study Rituximab combined with chemotherapy and interferon in follicular

J. Rossi, G. Salles, R. Bouabdallah, 2013 .

Validation of POD24 As a Robust Early Clinical Endpoint of Poor Survival in FL from 5,225 Patients on 13 Clinical Trials.

E. Kimby, E. Hoster, G. Salles, 2021, Blood.

Characterization of a specific androgen receptor in non-Hodgkin's lymphoma cells.

C. Sebban, J. Magaud, M. Menouni, 1984, Journal of steroid biochemistry.

study from the GELA patients with advanced follicular lymphoma: the GELF-94 randomized high-dose therapy with autologous stem cell transplantation in untreated Standard chemotherapy with interferon compared to CHOP followed by

G. Salles, B. Coiffier, R. Bouabdallah, 2013 .

Rituximab induction immunotherapy for first-line low-tumor-burden follicular lymphoma: survival analyses with 7-year follow-up.

G. Salles, H. Tilly, N. Brousse, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Efficacy and safety of the combination of rituximab, fludarabine, and mitoxantrone for rituximab‐naive, recurrent/refractory follicular non‐Hodgkin lymphoma with high tumor burden

M. Copin, P. Feugier, H. Tilly, 2010, Cancer.

A phase II trial of rituximab as adjuvant to intensive sequential chemotherapy in patients under 60 years with untreated poor-prognosis diffuse large B-cell lymphoma

R. Bouabdallah, L. Xerri, B. Chetaille, 2006, Bone Marrow Transplantation.

A risk model for thrombocytopenia requiring platelet transfusion after cytotoxic chemotherapy.

J. Blay, A. Ravaud, A. Cesne, 1998, Blood.

Outcome and prognostic factors in patients with mantle-cell lymphoma relapsing after autologous stem-cell transplantation: a retrospective study of the European Group for Blood and Marrow Transplantation (EBMT).

W. Stevens, M. Pfreundschuh, C. Sebban, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Event-Free Survival at 12 Months (EFS12) from Diagnosis Is a Robust Endpoint for Disease-Related Survival in Patients with Follicular Lymphoma in the Immunochemotherapy Era

J. Cerhan, A. Feldman, T. Habermann, 2014 .

Asymptomatic bone marrow involvement in patients presenting with cutaneous marginal zone B‐cell lymphoma

L. Thomas, G. Salles, F. Berger, 2008, The British journal of dermatology.

Interim Analysis of the Randomized Eortc/Lysa/Fil Intergroup H10 Trial On Early PET-Scan Driven Treatment Adaptation in Stage I/II Hodgkin Lymphoma

J. Raemaekers, M. Federico, C. Sebban, 2012 .

Long-term follow-up of an age-adapted C5R protocol followed by radiotherapy in 99 newly diagnosed primary CNS lymphomas: a prospective multicentric phase II study of the Groupe d'Etude des Lymphomes de l'Adulte (GELA).

J. Blay, B. Coiffier, O. Casasnovas, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Continuous-infusion daunorubicin and carboplatin for high-risk acute myeloid leukemia in the elderly.

C. Sebban, X. Thomas, E. Archimbaud, 1992, Leukemia.

Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: Final analysis of the GELA-GOELAMS FL2000 study with a 5-year follow-up

J. Rossi, G. Salles, R. Bouabdallah, 2007 .

Utility of post-therapy brain surveillance imaging in the detection of primary central nervous system lymphoma relapse.

J. Blay, F. Ducray, P. Biron, 2017, European journal of cancer.

Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study.

B. Coiffier, P. Feugier, H. Tilly, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Title: A Randomized Study of Interferon Alpha-2b Versus no Treatment as Consolidation

A. López-Guillermo, B. Coiffier, H. Holte, 2013 .

Influenza vaccination in patients with haematologic malignancies: analysis of practices in 200 patients in a single center.

J. Blay, P. Biron, C. Sebban, 2008, Bulletin du cancer.

Superiority of late over early intensification in relapsing/refractory aggressive non-Hodgkin's lymphoma: A randomized study from the GELA: LNH RP 93

G. Salles, B. Coiffier, H. Tilly, 1997 .

Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study

R. Bouabdallah, N. Brousse, C. Sebban, 2002, Leukemia.

High-dose chemotherapy with hematopoietic stem cell transplantation in patients with mantle cell or diffuse centrocytic non-Hodgkin’s lymphomas: a single center experience on 18 patients

J. Blay, P. Biron, C. Sebban, 1998, Bone Marrow Transplantation.

Primary cutaneous marginal zone B-cell lymphoma: a report of 9 cases.

F. Berger, B. Coiffier, C. Sebban, 1999, Journal of the American Academy of Dermatology.

Validation of POD24 As a Robust Early Clinical Endpoint of Poor Survival in Follicular Lymphoma: Results from the Follicular Lymphoma Analysis of Surrogacy Hypothesis (FLASH) Investigation Using Individual Data from 5,453 Patients on 13 Clinical Trials

E. Kimby, E. Hoster, G. Salles, 2017 .

Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy.

G. Salles, E. Campo, F. Cavalli, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High survival rate with the LMT-89 regimen in lymphoblastic lymphoma (LL), but not in T-cell acute lymphoblastic leukemia (T-ALL)

J. Bourhis, S. Koscielny, P. Biron, 2006, Leukemia.

Adult lymphoblastic lymphoma: a retrospective analysis of 92 patients under 61 years included in the LNH87/93 trials

R. Bouabdallah, S. Leprêtre, C. Sebban, 2003, Leukemia.

dic(4; 17)(p11;p11): A new recurrent chromosomal abnormality in chronic b‐lymphoid disorders

B. Coiffier, C. Sebban, J. Magaud, 1996, Genes, chromosomes & cancer.

Expression of BCL-2 proto-oncogene in adult acute lymphoblastic leukemia.

C. Sebban, C. Charrin, L. Campos, 1996, Leukemia.

Oral moxifloxacin or intravenous ceftriaxone for the treatment of low-risk neutropenic fever in cancer patients suitable for early hospital discharge

P. Biron, C. Sebban, T. Bachelot, 2008, Supportive Care in Cancer.

Parenthood in survivors of Hodgkin lymphoma: an EORTC-GELA general population case-control study.

J. Raemaekers, A. Allgeier, E. Noordijk, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Early Positron Emission Tomography Response-Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial.

J. Raemaekers, R. Bouabdallah, A. Stamatoullas, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma.

B. Pégourié, O. Decaux, C. Sebban, 2011, Blood.

Research controversies in management of oral mucositis

J. Blay, P. Biron, C. Sebban, 2000, Supportive Care in Cancer.

Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients

B. Pégourié, C. Sebban, P. Moreau, 2014, Leukemia.

myeloma autologous stem cell transplantation in newly diagnosed multiple thalidomide plus dexamethasone as induction treatment before Bortezomib plus dexamethasone versus reduced-dose bortezomib,

O. Decaux, C. Sebban, P. Moreau, 2012 .

Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte.

B. Coiffier, H. Tilly, C. Sebban, 2010, Blood.

Long-term results of the GELA study comparing R-CHOP and CHOP chemotherapy in older patients with diffuse large B-cell lymphoma show good survival in poor-risk patients

B. Coiffier, P. Feugier, H. Tilly, 2007 .

A randomised phase II study of the efficacy, safety and cost-effectiveness of pegfilgrastim and filgrastim after autologous stem cell transplant for lymphoma and myeloma (PALM study).

C. Sebban, P. Moreau, J. Bay, 2012, European journal of cancer.

Involved field irradiation (IFRT) does not improve outcome in patients with stage III/IV Hodgkin's lymphoma (HL) in complete remission after MOPP/ABV (M/A): Results of the randomised EORTC trial 20884

A. Hagenbeek, C. Sebban, U. Tirelli, 2001 .

Hepatic veno-occlusive disease after tandem autologous stem cell transplantation conditioned by melphalan

Sana Intidhar Labidi, P. Biron, C. Sebban, 2008, International journal of hematology.

Immunophenotype of adult acute lymphoblastic leukemia, clinical parameters, and outcome: an analysis of a prospective trial including 562 tested patients (LALA87). French Group on Therapy for Adult Acute Lymphoblastic Leukemia.

F. Sigaux, C. Sebban, M. Béné, 1994, Blood.

Prognostic value of high-sensitivity measurable residual disease assessment after front-line chemoimmunotherapy in chronic lymphocytic leukemia

Marc C. Jacob, M. Boubaya, J. Rossi, 2020, Leukemia.

Treatment of Acute Lymphoblastic Leukemia in the Elderly: An Evaluation of Interferon Alpha Given as a Single Agent After Complete Remission

R. Bouabdallah, H. Dombret, A. Delannoy, 2002, Leukemia & lymphoma.

Efficacy of lenalidomide in POEMS syndrome: A retrospective study of 20 patients

O. Decaux, C. Sebban, G. Deplanque, 2013, American journal of hematology.

Rituximab maintenance for 2-years significantly improves the outcome of patients with untreated high tumor burden follicular lymphoma after response to immunochemotherapy: results of the PRIMA study

A. Hagenbeek, G. Salles, A. López-Guillermo, 2010 .

Single Treatment with Rituximab Monotherapy for Low-Tumor Burden Follicular Lymphoma (FL): Survival Analyses with Extended Follow-Up (F/Up) of 7 Years.

G. Salles, H. Tilly, N. Brousse, 2006 .

Cost Effectiveness of Pegfilgrastim Versus Filgrastim After High-Dose Chemotherapy and Autologous Stem Cell Transplantation in Patients with Lymphoma and Myeloma

F. Jardin, P. Biron, C. Sebban, 2013, Applied Health Economics and Health Policy.

Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial.

A. Hagenbeek, P. Sonneveld, C. Gisselbrecht, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas.

J. Blay, M. van Glabbeke, J. Verweij, 2009, Cancer research.

Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL).

P. Gaulard, F. Berger, B. Coiffier, 2003, Blood.

Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone.

R. Greil, P. Gaulard, G. Salles, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.

P. Gaulard, G. Salles, B. Coiffier, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Sequentisl induction chemotherapy with vincristine, daunorubicin cyclophosphamide, and prednisone in adult acute lymphoblastic leukemia

C. Sebban, X. Thomas, E. Archimbaud, 1995, Annals of Hematology.

Adult acute lymphoblastic leukemia: a multicentric randomized trial testing bone marrow transplantation as postremission therapy. The French Group on Therapy for Adult Acute Lymphoblastic Leukemia.

C. Gisselbrecht, C. Sebban, É. Lepage, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adult Acute Lymphoblastic Leukemia — Results of the French AALL 87 Protocol with Different Strategies of Postremission Therapy

H. Dombret, A. Delannoy, C. Sebban, 1994 .

Burkitt lymphoma in adults: a prospective study of 72 patients treated with an adapted pediatric LMB protocol.

S. Koscielny, C. Sebban, J. Bosq, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Prognostic significance of received relative dose intensity in non-Hodgkin's lymphoma patients: application to LNH-87 protocol. The GELA. (Groupe d'Etude des Lymphomes de l'Adulte).

C Sebban, B. Coiffier, H. Tilly, 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

Quality-of-life-adjusted survival analysis of interferon alfa-2b treatment for advanced follicular lymphoma: an aid to clinical decision making.

R. Gelber, A. Goldhirsch, C. Gisselbrecht, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network

W. Klapper, E. Hoster, G. Salles, 2016, The Lancet.

Immunophenotype of Adult Acute Lymphoblastic Leukemia, Clinical Parameters, and Outcome: An Analysis of a Prospective Trial Including 562 Tested Patients (LALA87)

F. Sigaux, C. Sebban, M. Béné, 1994 .

Long-term follow-up of patients with newly diagnosed adult acute lymphoblastic leukemia: a single institution experience of 378 consecutive patients over a 21-year period

C. Sebban, J. Magaud, X. Thomas, 2001, Leukemia.

Long-Term Survival after Stem Cell Transplant in Adult Acute Lymphoblastic Leukemia

C. Sebban, X. Thomas, M. Michallet, 2003 .

Adult acute lymphocytic leukemia study testing chemotherapy and autologous and allogeneic transplantation. A follow-up report of the French protocol LALA 87.

C. Sebban, É. Lepage, J. Reiffers, 2000, Hematology/oncology clinics of North America.

Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d'Etude des Lymphomes de l'Adulte (GELA).

G. Salles, B. Coiffier, R. Bouabdallah, 2006, Blood.

Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation.

G. Salles, A. Stamatoullas, N. Brousse, 2001, Blood.

Treatment of acute myeloid leukemia in elderly patients. A retrospective study

B. Coiffier, C. Sebban, E. Archimbaud, 1988, Cancer.

Complete remission after first-line radio-chemotherapy as predictor of survival in extranodal NK/T cell lymphoma

G. Salles, F. Berger, B. Coiffier, 2012, Journal of Hematology & Oncology.

Phase II trial of plicamycin and hydroxyurea in acute myelogenous leukemia

C. Sebban, E. Archimbaud, D. Guyotat, 2004, Cancer Chemotherapy and Pharmacology.

Lymphoma recurrence 5 years or later following diffuse large B-cell lymphoma: clinical characteristics and outcome.

G. Salles, F. Berger, B. Coiffier, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol--a groupe d'Etude des lymphomes de l'Adulte study.

P. Gaulard, G. Salles, B. Coiffier, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparison of chemotherapy to radiotherapy as consolidation of complete or good partial response after six cycles of chemotherapy for patients with advanced Hodgkin's disease: results of the groupe d'études des lymphomes de l'Adulte H89 trial.

F. Berger, C. Sebban, É. Lepage, 2000, Blood.

Randomized comparison of ACVBP and m-BACOD in the treatment of patients with low-risk aggressive lymphoma: the LNH87-1 study. Groupe d'Etudes des Lymphomes de l'Adulte.

B. Coiffier, H. Tilly, P. Biron, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Intensive chemotherapy in aggressive lymphomas: updated results of LNH-80 protocol and prognostic factors affecting response and survival.

F. Berger, B. Coiffier, C. Sebban, 1987, Blood.

Long-term outcome with pentostatin treatment in hairy cell leukemia patients. A French retrospective study of 238 patients

B. Coiffier, B. Grosbois, C. Sebban, 2003, Leukemia.

Severe IgA-mediated autoimmune haemolytic anaemia in Hodgkin lymphoma: A very rare event

P. Biron, C. Sebban, D. Rigal, 2007, Leukemia & lymphoma.

Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 Randomized Study.

C. Copie-Bergman, F. Jardin, A. López-Guillermo, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Early event status informs subsequent outcome in newly diagnosed follicular lymphoma

J. Cerhan, G. Salles, B. Coiffier, 2016, American journal of hematology.

Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trial

P. Gaulard, G. Salles, A. Rahmouni, 2013, Haematologica.

Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma.

A. Hagenbeek, G. Salles, F. d'Amore, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Utility of routine post-therapy surveillance imaging in diffuse large B-cell lymphoma.

J. Cerhan, T. Habermann, S. Ansell, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma

R. Houot, G. Salles, P. Feugier, 2013, Haematologica.

A case of advanced non-Hodgkin's lymphoma involving the prostate: staging and treatment monitoring using F-18 FDG PET/CT imaging.

C. Sebban, C. Chassagne‐Clément, P. Heudel, 2010, Clinical nuclear medicine.

Allogeneic bone marrow transplantation in adult acute lymphoblastic leukemia in first complete remission: a comparative study. French Group of Therapy of Adult Acute Lymphoblastic Leukemia.

C. Sebban, É. Lepage, J. Reiffers, 1994, Journal of Clinical Oncology.

High total metabolic tumor volume at baseline allows discrimination of survival even in patients aged 60 to 80 years responding to R-CHOP.

L. Vercellino, P. Gaulard, G. Salles, 2020, Blood.

Clinical characteristics and outcome of isolated extracerebral relapses of primary central nervous system lymphoma: a case series

J. Blay, S. Leprêtre, H. Tilly, 2011, Hematological oncology.

90Yttrium ibritumomab tiuxetan (Zevalin) combined with BEAM (Z-BEAM) conditioning regimen plus autologous stem cell transplantation in relapsed or refractory. follicular lymphoma. GELA phase II study

B. Coiffier, H. Tilly, C. Gisselbrecht, 2007 .

Age-adapted induction treatment of acute lymphoblastic leukemia in the elderly and assessment of maintenance with interferon combined with chemotherapy. A multicentric prospective study in forty patients

R. Bouabdallah, P. Cony-Makhoul, A. Delannoy, 1997, Leukemia.

Quality of life-adjusted survival analysis of high-dose therapy with autologous bone marrow transplantation versus sequential chemotherapy for patients with aggressive lymphoma in first complete remission. Groupe d'Etude les Lymphomes de l'Adulte (GELA).

C Sebban, G. Salles, R. Bouabdallah, 2000, Blood.

Successful treatment of adult acute lymphoblastic leukemia after relapse with prednisone, intermediate‐dose cytarabine, mitoxantrone, and etoposide (PAME) chemotherapy

C. Gisselbrecht, C. Sebban, X. Troussard, 1990, Cancer.

Rituximab Combined to ACVBP (R-ACVBP) Supported by Pegfilgrastim as a New Inductive Treatment Followed by High-Dose Consolidative Autotransplantation (HDC) for Poor Risk Diffuse Large B-Cell Lymphoma (DLBCL) in First-Line. Results of LNH 03–39B. A GELA Study.

B. Coiffier, J. Jais, O. Casasnovas, 2007 .

Follicular large-cell lymphoma treated with intensive chemotherapy: an analysis of 89 cases included in the LNH87 trial and comparison with the outcome of diffuse large B-cell lymphoma. Groupe d'Etude des Lymphomes de l'Adulte.

P. Gaulard, B. Coiffier, J. Diebold, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Risk-adapted salvage treatment with single or tandem autologous stem-cell transplantation for first relapse/refractory Hodgkin's lymphoma: results of the prospective multicenter H96 trial by the GELA/SFGM study group.

G. Salles, R. Bouabdallah, J. Jais, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic value of early response to chemotherapy assessed by the day 15 bone marrow aspiration in adult acute lymphoblastic leukemia: a prospective analysis of 437 cases and its application for designing induction chemotherapy trials.

C. Sebban, G. Browman, É. Lepage, 1995, Leukemia research.

Survival Impact of Rituximab Combined to ACVBP (R-ACVBP) in 209 Poor Risk Diffuse Large B-Cell Lymphoma (DLBCL) Patients Treated with Upfront High-Dose Consolidative Autotransplantation (HDC) : A GELA Phase II Study

B. Coiffier, O. Casasnovas, P. Feugier, 2008 .

Age is a prognostic factor even among patients with multiple myeloma younger than 66 years treated with high-dose melphalan: the IFM experience on 2316 patients

B. Pégourié, C. Sebban, P. Moreau, 2014, Haematologica.

Autologous BMT for post-remission therapy in adult ALL: an immunological approach. For The French Group of Therapy of Adult ALL.

C. Gisselbrecht, C. Sebban, X. Troussard, 1994, Leukemia & lymphoma.

Primary cerebral lymphomas: unsolved issues regarding first-line treatment, follow-up, late neurological toxicity and treatment of relapses. The FNCLCC. French Fédération Nationale des Centres de Lutte contre le Cancer.

J. Blay, P. Biron, C. Sebban, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

Long‐term fatigue in survivors of non‐Hodgkin lymphoma: The Lymphoma Study Association SIMONAL cross‐sectional study

G. Salles, J. Jais, P. Feugier, 2019, Cancer.

Etoposide pharmacokinetics impact the outcomes of lymphoma patients treated with BEAM regimen and ASCT: a multicenter study of the LYmphoma Study Association (LYSA)

G. Salles, O. Casasnovas, H. Tilly, 2015, Cancer Chemotherapy and Pharmacology.

Combination of rituximab with chemotherapy in diffuse large B‐cell lymphoma. Evaluation in daily practice before and after approval of rituximab in this indication

J. Blay, P. Biron, C. Sebban, 2008, Hematological oncology.

Serum cytokines in follicular lymphoma. Correlation of TGF-β and VEGF with survival

Pierre Biron, Sylvie Chabaud, Thérèse Gargi, 2009, Annals of Hematology.

for the Groupe d'Etude des Lymphomes de l'Adulte (GELA)

R. Houot, G. Salles, P. Feugier, 2013 .

1p22 and 1p32 Deletions Are Independent Prognosis Factors in Young Patients with Myeloma: The IFM Experience On 1195 Patients

B. Pégourié, C. Sebban, P. Moreau, 2012 .

Treatment of low‐grade non‐Hodgkin's lymphomas: Assessment of doxorubicin in a controlled trial

B. Coiffier, C. Gisselbrecht, M. Boiron, 1990, Hematological oncology.

Impact of the introduction of rituximab in first‐line follicular lymphoma: a retrospective study of 247 unselected patients referred to a single institution with a long‐term follow‐up

P. Biron, C. Sebban, C. Chassagne‐Clément, 2015, Hematological oncology.

Evidence of time‐dependent prognostic factors predicting early death but not long‐term outcome in primary CNS lymphoma: a study of 91 patients

J. Blay, Y. Drouet, J. Honnorat, 2013, Hematological oncology.

ABVD or BEACOPPbaseline along with involved-field radiotherapy in early-stage Hodgkin Lymphoma with risk factors: Results of the European Organisation for Research and Treatment of Cancer (EORTC)-Groupe d'Étude des Lymphomes de l'Adulte (GELA) H9-U intergroup randomised trial.

J. Raemaekers, G. Salles, D. de Jong, 2017, European journal of cancer.

Rituximab induction immunotherapy for first-line low-tumor-burden follicular lymphoma: survival analyses with 7-year follow-up.

G. Salles, H. Tilly, N. Brousse, 2012 .

Design and validation of a bedside decision instrument to elicit a patient's preference concerning allogenic bone marrow transplantation in chronic myeloid leukemia

C Sebban, A Gafni, A. Gafni, 1995, American journal of hematology.

Maintenance with low-dose cytarabine for acute myeloid leukemia in complete remission

C. Sebban, X. Thomas, E. Archimbaud, 1992, Annals of Hematology.

Schnitzler syndrome associated with systemic marginal zone B‐cell lymphoma

L. Thomas, F. Berger, C. Sebban, 2006, The British journal of dermatology.

Use of F-18 FDG PET/CT in non-Hodgkin lymphoma with central nervous system involvement.

J. Blay, C. Sebban, P. Thiesse, 2011, Clinical nuclear medicine.

Cryopreservation, semen use and the likelihood of fatherhood in male Hodgkin lymphoma survivors: an EORTC-GELA Lymphoma Group cohort study.

J. Raemaekers, B. Coiffier, A. Allgeier, 2014, Human reproduction.

Influence of daunorubicin and cytarabine sequencing on the outcome of therapy in acute myelogenous leukemia: a randomized trial.

P. Adeleine, C. Sebban, E. Archimbaud, 1987, Cancer treatment reports.

Monotherapy with pixantrone in histologically confirmed relapsed or refractory aggressive B‐cell non‐Hodgkin lymphoma: post‐hoc analyses from a phase III trial

B. Coiffier, P. Zinzani, C. Sebban, 2016, British journal of haematology.

Independent Predictive Value of PET-CT Pre Transplant in Relapsed and Refractory Patients with CD20 Diffuse Large B-Cell Lymphoma (DLBCL) Included in the CORAL Study.

N. Schmitz, S. Montoto, C. Gisselbrecht, 2009 .

[Solitary plasmacytoma of the sphenoid. A case report].

C. Sebban, J. Guyotat, P. Bret, 2002, Neuro-chirurgie.

Newly Diagnosed Diffuse Large B-Cell Lymphoma Patients Treated with Immunochemotherapy Who Are Alive and Progression Free 12 Months After Diagnosis Have a Subsequent Overall Survival Similar to That of the General Population

J. Cerhan, T. Habermann, S. Slager, 2012 .

Pattern of Care and Outcomes of Adolescent and Young Adults with Lymphoma Treated in the Rhône-Alpes Region.

G. Salles, F. Berger, P. Cony-Makhoul, 2019, Journal of adolescent and young adult oncology.

Clinical and pharmacokinetic phase II study of fotemustine in refractory and relapsing multiple myeloma patients.

B. Coiffier, C. Sebban, C. Dumontet, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Rituximab Combined to ACVBP (R-ACVBP) as a New Inductive Treatment Followed by High-Dose Consolidative Autotransplantation (HDC) for Poor Risk Diffuse Large B-Cell Lymphoma (DLBCL) in First-Line. Preliminary Results on 119 Patients of a GELA Phase II Study.

B. Coiffier, O. Casasnovas, H. Tilly, 2006 .

Acute Lymphoblastic Leukemia 562 tested patients (LALA87). French Group on Therapy for Adult including parameters, and outcome: an analysis of a prospective trial Immunophenotype of adult acute lymphoblastic leukemia, clinical

C. Sebban, A. Bernard, H. Jouault, 2011 .

Hodgkins disease

B. Fervers, C. Sebban, F. Giammarile, 2001, British Journal of Cancer.

Analysis of Minimal Residual Disease in Follicular Lymphoma Patients in Gadolin, a Phase III Study of Obinutuzumab Plus Bendamustine Versus Bendamustine in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

E. Hoster, J. Gribben, L. Sehn, 2015 .

A randomized study of interferon α-2b versus no treatment as consolidation after high dose therapy and autologous stem cell transplantation for patients with relapsed lymphoma.

A. López-Guillermo, B. Coiffier, H. Holte, 2013, The oncologist.

Chemotherapy combined with zidovudine and GM-CSF in human immunodeficiency virus-related non-Hodgkin's lymphoma.

R. Tubiana, C. Sebban, É. Lepage, 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

Treatment of Adult Acute Lymphoblastic Leukemia Long Term Results of a Prospective Study: LALA 87

A. Delannoy, C. Sebban, É. Lepage, 2001 .

[Severe quantitative bone marrow insufficiency: results of treatment with high-dose antilymphocyte serum].

B. Coiffier, C. Sebban, M. Ffrench, 1985, Presse medicale.

Is Early Response to Chemotherapy a Useful Prognostic Factor in Adult Acute Lymphoblastic Leukemia

C. Sebban, É. Lepage, X. Troussard, 1994 .

Primary cutaneous marginal zone B-cell lymphoma: a report of 9 cases.

F. Berger, B. Coiffier, C. Sebban, 1999, Journal of the American Academy of Dermatology.

[Epidemiology of non-Hodgkin's lymphoma: recent data].

P. Biron, C. Sebban, I. Treilleux, 1999, Bulletin du cancer.

Evaluation in the Context of Daily Practice of Follicular Lymphoma patients' Outcome Before and After Approval of Rituximab in First Line Therapy in This Indication: Results of a Retrospective Analysis of 247 Unselected Patients with a 5-Year Median of Follow-up,

J. Blay, P. Biron, C. Sebban, 2011 .

Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study.

J. Rossi, G. Salles, R. Bouabdallah, 2008, Blood.

Efficacy and safety of the combination of rituximab, fludarabine, and mitoxantrone for rituximab‐naive, recurrent/refractory follicular non‐Hodgkin lymphoma with high tumor burden

M. Copin, P. Feugier, H. Tilly, 2010, Cancer.

Long term results of the GELA study, R-CHOP vs. CHOP in elderly patients with diffuse large B-cell lymphoma.

G. Salles, R. Bouabdallah, P. Feugier, 2004 .

Peripheral Blood Stem Cells Mobilization with G-CSF (FILGRASTIM) Alone for Autologous Transplant in Myeloid and Lymphoid Malignancies

C. Sebban, E. Archimbaud, I. Philip, 1996 .

Parenthood in survivors of Hodgkin lymphoma: An EORTC-GELA general population case-control study.

J. Raemaekers, A. Allgeier, E. Noordijk, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.